CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer. [electronic resource]
Producer: 20191213Description: 130-140 p. digitalISSN:- 1872-7980
- Acrylamides -- pharmacology
- Aminoquinolines -- pharmacology
- Animals
- Apoptosis -- drug effects
- Breast Neoplasms -- drug therapy
- Cell Cycle Checkpoints -- drug effects
- Cell Line, Tumor
- Cell Proliferation
- Cyclin-Dependent Kinase 4 -- antagonists & inhibitors
- Cyclin-Dependent Kinase 6 -- antagonists & inhibitors
- Female
- G1 Phase -- drug effects
- Gene Expression Regulation, Neoplastic -- drug effects
- Humans
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Piperazines -- pharmacology
- Pyridines -- pharmacology
- Receptor, ErbB-2 -- genetics
- Resting Phase, Cell Cycle -- drug effects
- Xenograft Model Antitumor Assays -- methods
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.